| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
21 |
27 |
56 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mueller Brian |
SVP, Corporate Controller |
• – – |
2018-06-22 |
4 |
AS |
$99.50 |
$312,928 |
D/D |
(3,145) |
12,375 |
|
- |
|
| Mueller Brian |
SVP, Corporate Controller |
• – – |
2018-06-22 |
4 |
OE |
$28.23 |
$70,321 |
D/D |
2,491 |
14,866 |
|
- |
|
| Mueller Brian |
SVP, Corporate Controller |
• – – |
2018-06-15 |
4 |
AS |
$94.50 |
$190,985 |
D/D |
(2,021) |
13,029 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2018-06-14 |
4 |
AS |
$90.00 |
$2,790,085 |
D/D |
(31,000) |
155,167 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2018-06-14 |
4 |
OE |
$21.51 |
$1,067,380 |
D/D |
31,000 |
175,848 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-06-13 |
4 |
OE |
$14.39 |
$14,390 |
D/D |
1,000 |
285,290 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2018-06-11 |
4 |
AS |
$90.31 |
$129,685 |
D/D |
(1,436) |
50,135 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
7,480 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
9,210 |
|
- |
|
| Slamon Dennis |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
14,185 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
19,160 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
56,610 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
25,360 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
8,990 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
34,110 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
42,685 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$143,813 |
D/D |
(1,562) |
83,276 |
|
- |
|
| Mueller Brian |
SVP, Corporate Controller |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$31,856 |
D/D |
(346) |
15,050 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$157,532 |
D/D |
(1,711) |
61,070 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$130,187 |
D/D |
(1,414) |
51,571 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$130,187 |
D/D |
(1,414) |
86,950 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$178,063 |
D/D |
(1,934) |
155,167 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-06-04 |
4 |
D |
$92.07 |
$580,962 |
D/D |
(6,310) |
284,290 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2018-05-17 |
4 |
OE |
$38.59 |
$578,850 |
D/D |
15,000 |
51,310 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-05-17 |
4 |
AS |
$88.66 |
$1,662,356 |
D/D |
(18,750) |
290,600 |
|
- |
|
2582 Records found
|
|
Page 27 of 104 |
|
|
1.44 (1.6%) 
